作者
Philipp Georg,Rosario Astaburuaga-García,Lorenzo Bonaguro,Sophia Brumhard,Laura Michalick,Lena J. Lippert,Tomislav Kostevc,Christiane Gäbel,Maria Schneider,Mathias Streitz,Vadim Demichev,Ioanna D. Gemünd,Matthias Barone,Pinkus Tober‐Lau,Elisa T. Helbig,David Hillus,L. A. Petrov,Julia Stein,Hannah-Philine Dey,Daniela Paclik,Christina Iwert,Michael Mülleder,Simran Kaur Aulakh,Sonja Djudjaj,Roman David Bülow,Henrik E. Mei,Axel Schulz,Andreas Thiel,Stefan Hippenstiel,Antoine‐Emmanuel Saliba,Roland Eils,Irina Lehmann,Marcus Mall,Sebastian Stricker,Jobst Röhmel,Victor M. Corman,Dieter Beule,Emanuel Wyler,Markus Landthaler,Benedikt Obermayer,Saskia von Stillfried,Peter Boor,Münevver Demir,Hans Wesselmann,Norbert Suttorp,Alexander Uhrig,Holger Müller-Redetzky,Jacob Nattermann,Wolfgang M. Kuebler,Christian Meisel,Markus Ralser,Joachim L. Schultze,Anna C. Aschenbrenner,Charlotte Thibeault,Florian Kurth,Leif Erik Sander,Nils Blüthgen,Birgit Sawitzki
摘要
Severe COVID-19 is linked to both dysfunctional immune response and unrestrained immunopathology, and it remains unclear whether T cells contribute to disease pathology. Here, we combined single-cell transcriptomics and single-cell proteomics with mechanistic studies to assess pathogenic T cell functions and inducing signals. We identified highly activated CD16+ T cells with increased cytotoxic functions in severe COVID-19. CD16 expression enabled immune-complex-mediated, T cell receptor-independent degranulation and cytotoxicity not found in other diseases. CD16+ T cells from COVID-19 patients promoted microvascular endothelial cell injury and release of neutrophil and monocyte chemoattractants. CD16+ T cell clones persisted beyond acute disease maintaining their cytotoxic phenotype. Increased generation of C3a in severe COVID-19 induced activated CD16+ cytotoxic T cells. Proportions of activated CD16+ T cells and plasma levels of complement proteins upstream of C3a were associated with fatal outcome of COVID-19, supporting a pathological role of exacerbated cytotoxicity and complement activation in COVID-19.